AROMASIN Drug Patent Profile

When do Aromasin patents expire, and when can generic versions of Aromasin launch?

Aromasin is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in AROMASIN is exemestane. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the exemestane profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aromasin

A generic version of AROMASIN was approved as exemestane by HIKMA on April 1^st, 2011.

Summary for AROMASIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	102
Clinical Trials:	85
Drug Prices:	Drug price information for AROMASIN
What excipients (inactive ingredients) are in AROMASIN?	AROMASIN excipients list
DailyMed Link:	AROMASIN at DailyMed

See drug prices for AROMASIN

Recent Clinical Trials for AROMASIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Breast Cancer Research Foundation	Phase 2
NRG Oncology	Phase 2
Oana Danciu	Phase 2

See all AROMASIN clinical trials

Pharmacology for AROMASIN

Drug Class	Aromatase Inhibitor
Mechanism of Action	Aromatase Inhibitors

US Patents and Regulatory Information for AROMASIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	AROMASIN	exemestane	TABLET;ORAL	020753-001	Oct 21, 1999	AB	RX	Yes	Yes

Expired US Patents for AROMASIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	AROMASIN	exemestane	TABLET;ORAL	020753-001	Oct 21, 1999
Pfizer	AROMASIN	exemestane	TABLET;ORAL	020753-001	Oct 21, 1999

International Patents for AROMASIN

See the table below for patents covering AROMASIN around the world.

Country	Patent Number	Title	Estimated Expiration
Belgium	905067
Czechoslovakia	257794	METHOD OF SUBSTITUTED ANDROSTA-1,4-DIENE-3,17-DIENES PRODUCTION
United Kingdom	2177700	SUBSTITUTED ANDROSTA-1,4-DIENE-3,17-DIONES AND PROCESS FOR THEIR PREPARATION
Czechoslovakia	258498	METHOD OF ANDROSTA-1,4-DIEN-3,17-DIONES PRODUCTION
Finland	862871
New Zealand	216763	6-ALKYLIDENANDROSTA-1,4-DIENE-3,17-DIONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS

AROMASIN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Aromasin

Overview of Aromasin

Aromasin, also known as exemestane, is an aromatase inhibitor used primarily in the treatment of breast cancer, particularly in postmenopausal women. It works by inhibiting the enzyme aromatase, which is involved in the production of estrogen, a hormone that can promote the growth of breast cancer cells.

Market Drivers

Increasing Prevalence of Breast Cancer

The global aromatase inhibitors market, including Aromasin, is driven by the rising prevalence of breast cancer. In the United States alone, approximately 255,000 cases of breast cancer are registered every year, with more than 42,000 women and 500 men dying from the disease annually[1].

Aging Population

The geriatric population is more likely to develop breast cancer, and since the global population is aging, this demographic shift is expected to increase the demand for aromatase inhibitors like Aromasin[1].

Healthcare Infrastructure and Investment

The growth in healthcare expenditure, especially in developing economies, is improving healthcare infrastructure and increasing the adoption of advanced medical technologies and drugs. This trend is expected to boost the demand for aromatase inhibitors[1].

Research and Development

Strategic collaborations between public and private sector players are driving research and development activities in the field of novel drugs and medical technologies. This includes the development of new aromatase inhibitors and improved treatment protocols, which will further propel the market[1].

Market Segmentation

By Product

Aromatase inhibitors, including Aromasin, are segmented into various products such as letrozole, exemestane (Aromasin), testolactone, and anastrozole. Each of these products has its own market share and growth trajectory[3].

By Distribution Channel

The market is also segmented by distribution channels, including hospital pharmacies, online pharmacies, retail pharmacies, and others. The ease of access and convenience offered by these channels influence the market dynamics[3].

By End Users

The aromatase inhibitors market is segmented into hospitals, homecare, specialty clinics, and others. The demand from these end users varies based on the healthcare infrastructure and patient preferences[1].

Financial Trajectory

Revenue Growth

The global aromatase inhibitors market, which includes Aromasin, is expected to grow at a Compound Annual Growth Rate (CAGR) of around 5.1% to 5.6% during the forecast period from 2022 to 2030. This growth is projected to result in a market size of approximately USD 532.04 million by 2030[1][3].

Regional Performance

North America dominates the aromatase inhibitors market due to the high prevalence of breast cancer and well-developed healthcare infrastructure. However, the Asia-Pacific region is expected to exhibit the highest growth rate due to increasing patient pools, rising healthcare investments, and growing government support[1][3].

Key Players

Companies like Pfizer Inc., Novartis AG, F. Hoffmann-La Roche, and Eisai Co. Ltd are significant players in the aromatase inhibitors market. These companies are investing heavily in research and development, which is driving the market forward. For instance, Pfizer's financial reports indicate strong revenue growth driven by various pharmaceutical products, including those in the oncology segment[5].

Impact of COVID-19

The COVID-19 pandemic had a slight setback on the aromatase inhibitors market, primarily due to delays in diagnostic rates and supply shortages of drugs. However, patients with breast cancer were at a higher risk of contracting COVID-19, which highlighted the need for continued treatment and care[1].

Recent Developments

Recent developments in the field include the approval of new treatments and the advancement of research. For example, the University of Sussex identified the role of lemur tyrosine kinase 3 (LMTK3) in breast cancer cell proliferation, which could lead to the development of new targeted therapies[1].

Prevention and Risk Reduction

Studies have shown that aromatase inhibitors like Aromasin can reduce the risk of breast cancer in high-risk women. A study presented at the American Society of Clinical Oncology’s conference demonstrated that women taking Aromasin developed breast cancer at a lower rate than those taking a placebo[4].

Key Takeaways

• Growing Demand: The aromatase inhibitors market, including Aromasin, is driven by the increasing prevalence of breast cancer and an aging population.
• Regional Growth: North America leads the market, but the Asia-Pacific region is expected to show the highest growth rate.
• Financial Performance: The market is projected to grow at a CAGR of around 5.1% to 5.6% during the forecast period.
• COVID-19 Impact: The pandemic caused temporary setbacks but highlighted the ongoing need for breast cancer treatments.
• Research and Development: Continuous R&D activities are driving the development of new and effective treatments.

FAQs

Q: What is Aromasin used for?

Aromasin, or exemestane, is used primarily in the treatment of breast cancer, especially in postmenopausal women, by inhibiting the enzyme aromatase which is involved in estrogen production.

Q: How does the aging population affect the aromatase inhibitors market?

The aging population increases the demand for aromatase inhibitors since breast cancer prevalence is higher in older individuals.

Q: What is the impact of COVID-19 on the aromatase inhibitors market?

COVID-19 caused delays in diagnostic rates and supply shortages, but it also highlighted the critical need for continued breast cancer treatment.

Q: Which regions are expected to drive the growth of the aromatase inhibitors market?

North America currently dominates the market, but the Asia-Pacific region is expected to exhibit the highest growth rate due to increasing patient pools and healthcare investments.

Q: What are some recent developments in the aromatase inhibitors market?

Recent developments include the identification of new targets like LMTK3 for breast cancer treatment and the approval of new combination therapies, such as Keytruda with chemotherapy for triple-negative breast cancer[1].